Open AccessExpression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma
Author(s) -
WeiChih Su,
ShihChang Chuang,
Yu-Chu Wang,
Lin-An Chen,
Jianwei Huang,
Wai Hoong Chang,
ShenNien Wang,
KingTeh Lee,
Chang-Shen Lin,
KungKai Kuo
Publication year - 2020
Publication title -
disease markers. section a, cancer biomarkers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.959
H-Index - 41
eISSN - 1875-8592
pISSN - 1574-0153
DOI - 10.3233/cbm-190507
Subject(s) - sorafenib , hepatocellular carcinoma , medicine , foxm1 , oncology , cancer research , cancer , cell cycle
Effective prognostic biomarkers and powerful target-therapeutic drugs are needed for improving the treatment of Hepatocellular carcinoma (HCC).